|
1
|
Alix-Panabieres C and Pantel K:
Circulating tumor cells: Liquid biopsy of cancer. Clin Chem.
59:110–118. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bragado P, Sosa MS, Keely P, Condeelis J
and Aguirre-Ghiso JA: Microenvironments dictating tumor cell
dormancy. Recent Results Cancer Res. 195:25–39. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Andergassen U, Hofmann S, Kölbl AC,
Schindlbeck C, Neugebauer J, Hutter S, Engelstädter V, Ilmer M,
Friese K and Jeschke U: Detection of tumor cell-specific mRNA in
the peripheral blood of patients with breast cancer-evaluation of
several markers with real-time reverse transcription-PCR. Int J Mol
Sci. 14:1093–1104. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Andreopoulou E, Yang LY, Rangel KM, Reuben
JM, Hsu L, Krishnamurthy S, Valero V, Fritsche HA and Cristofanilli
M: Comparison of assay methods for detection of circulating tumor
cells in metastatic breast cancer: AdnaGen adna test breast cancer
select/detect versus veridex cell search™ system. Int J Cancer.
130:1590–1597. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bednarz-Knoll N, Alix-Panabières C and
Pantel K: Clinical relevance and biology of circulating tumor
cells. Breast Cancer Res. 13:2282011. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Diel IJ, Solomayer EF, Costa SD, Gollan C,
Goerner R, Wallwiener D, Kaufmann M and Bastert G: Reduction in new
metastases in breast cancer with adjuvant clodronate treatment. N
Engl J Med. 339:357–363. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dowsett M and Dunbier AK: Emerging
biomarkers and new understanding of traditional markers in
personalized therapy for breast cancer. Clin Cancer Res.
14:8019–8026. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dowsett M, Procter M, McCaskill-Stevens W,
de Azambuja E, Dafni U, Rueschoff J, Jordan B, Dolci S, Abramovitz
M, Stoss O, et al: Disease-free survival according to degree of
HER2 amplification for patients treated with adjuvant chemotherapy
with or without 1 year of trastuzumab: The HERA trial. J Clin
Oncol. 27:2962–2969. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dunnwald LK, Rossing MA and Li CI: Hormone
receptor status, tumor characteristics and prognosis: A prospective
cohort of breast cancer patients. Breast Cancer Res. 9:R62007.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Franken B, de Groot MR, Mastboom WJ,
Vermes I, van der Palen J, Tibbe AG and Terstappen LW: Circulating
tumor cells, disease recurrence and survival in newly diagnosed
breast cancer. Breast Cancer Res. 14:R1332012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Braun S, Vogl FD, Naume B, Janni W,
Osborne MP, Coombes RC, Schlimok G, Diel IJ, Gerber B, Gebauer G,
et al: A pooled analysis of bone marrow micrometastasis in breast
cancer. N Engl J Med. 353:793–802. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Graves H and Czerniecki BJ: Circulating
tumor cells in breast cancer patients: An evolving role in patient
prognosis and disease progression. Patholog Res Int.
2011:6210902011.PubMed/NCBI
|
|
13
|
Guarino M: Epithelial-mesenchymal
transition and tumour invasion. Int J Biochem Cell Biol.
39:2153–2160. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kölbl AC, Jeschke U and Andergassen U: The
significance of epithelial-to-mesenchymal transition for
circulating tumor cells. Int J Mol Sci. 17:E13082016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tiwari N, Gheldof A, Tatari M and
Christofori G: EMT as the ultimate survival mechanism of cancer
cells. Semin Cancer Biol. 22:194–207. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gorges TM, Tinhofer I, Drosch M, Röse L,
Zollner TM, Krahn T and von Ahsen O: Circulating tumour cells
escape from EpCAM-based detection due to epithelial-to-mesenchymal
transition. BMC Cancer. 12:1782012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Raimondi C, Gradilone A, Naso G, Vincenzi
B, Petracca A, Nicolazzo C, Palazzo A, Saltarelli R, Spremberg F,
Cortesi E and Gazzaniga P: Epithelial-mesenchymal transition and
stemness features in circulating tumor cells from breast cancer
patients. Breast Cancer Res Treat. 130:449–455. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hugo H, Ackland ML, Blick T, Lawrence MG,
Clements JA, Williams ED and Thompson EW: Epithelial-mesenchymal
and mesenchymal-epithelial transitions in carcinoma progression. J
Cell Physiol. 213:374–383. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nieto MA: Epithelial plasticity: A common
theme in embryonic and cancer cells. Science. 342:12348502013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yao D, Dai C and Peng S: Mechanism of the
mesenchymal-epithelial transition and its relationship with
metastatic tumor formation. Mol Cancer Res. 9:1608–1620. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kurec AS, Baltrucki L, Mason DY and Davey
FR: Use of the APAAP method in the classification and diagnosis of
hematologic disorders. Clin Lab Med. 8:223–236. 1988.PubMed/NCBI
|
|
22
|
Noack F, Schmitt M, Bauer J, Helmecke D,
Krüger W, Thorban S, Sandherr M, Kuhn W, Graeff H and Harbeck N: A
new approach to phenotyping disseminated tumor cells:
Methodological advances and clinical implications. Int J Biol
Markers. 15:100–104. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ignatiadis M, Kallergi G, Ntoulia M,
Perraki M, Apostolaki S, Kafousi M, Chlouverakis G, Stathopoulos E,
Lianidou E, Georgoulias V and Mavroudis D: Prognostic value of the
molecular detection of circulating tumor cells using a multimarker
reverse transcription-PCR assay for cytokeratin 19, mammaglobin A
and HER2 in early breast cancer. Clin Cancer Res. 14:2593–2600.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ignatiadis M, Xenidis N, Perraki M,
Apostolaki S, Politaki E, Kafousi M, Stathopoulos EN, Stathopoulou
A, Lianidou E, Chlouverakis G, et al: Different prognostic value of
cytokeratin-19 mRNA positive circulating tumor cells according to
estrogen receptor and HER2 status in early-stage breast cancer. J
Clin Oncol. 25:5194–5202. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Saloustros E and Mavroudis D: CTCs in
primary breast cancer (II). Recent Results Cancer Res. 195:187–192.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Saloustros E, Perraki M, Apostolaki S,
Kallergi G, Xyrafas A, Kalbakis K, Agelaki S, Kalykaki A,
Georgoulias V and Mavroudis D: Cytokeratin-19 mRNA-positive
circulating tumor cells during follow-up of patients with operable
breast cancer: Prognostic relevance for late relapse. Breast Cancer
Res. 13:R602011. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Soltani S, Mokarian F and Panjehpour M:
The expression of CK-19 gene in circulating tumor cells of blood
samples of metastatic breast cancer women. Res Pharm Sci.
10:485–496. 2015.PubMed/NCBI
|
|
28
|
Zhao S, Yang H, Zhang M, Zhang D, Liu Y,
Liu Y, Song Y, Zhang X, Li H, Ma W and Zhang Q: Circulating tumor
cells (CTCs) detected by triple-marker EpCAM, CK19 and hMAM RT-PCR
and their relation to clinical outcome in metastatic breast cancer
patients. Cell Biochem Biophys. 65:263–273. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tunca B, Egeli U, Cecener G, Tezcan G,
Gökgöz S, Tasdelen I, Bayram N, Tolunay S, Umut G, Demirdogen E, et
al: CK19, CK20, EGFR and HER2 status of circulating tumor cells in
patients with breast cancer. Tumori. 98:243–251. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kallergi G, Papadaki MA, Politaki E,
Mavroudis D, Georgoulias V and Agelaki S: Epithelial to mesenchymal
transition markers expressed in circulating tumour cells of early
and metastatic breast cancer patients. Breast Cancer Res.
13:R592011. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Blanco MJ, Moreno-Bueno G, Sarrio D,
Locascio A, Cano A, Palacios J and Nieto MA: Correlation of Snail
expression with histological grade and lymph node status in breast
carcinomas. Oncogene. 21:3241–3246. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Peinado H, Olmeda D and Cano A: Snail, Zeb
and bHLH factors in tumour progression: an alliance against the
epithelial phenotype? Nat Rev Cancer. 7:415–428. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Vega S, Morales AV, Ocaña OH, Valdés F,
Fabregat I and Nieto MA: Snail blocks the cell cycle and confers
resistance to cell death. Genes Dev. 18:1131–1143. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Moody SE, Perez D, Pan TC, Sarkisian CJ,
Portocarrero CP, Sterner CJ, Notorfrancesco KL, Cardiff RD and
Chodosh LA: The transcriptional repressor Snail promotes mammary
tumor recurrence. Cancer Cell. 8:197–209. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hajra KM, Chen DY and Fearon ER: The SLUG
zinc-finger protein represses E-cadherin in breast cancer. Cancer
Res. 62:1613–1618. 2002.PubMed/NCBI
|
|
36
|
Villarejo A, Cortes-Cabrera A,
Molina-Ortiz P, Portillo F and Cano A: Differential role of Snail1
and Snail2 zinc fingers in E-cadherin repression and epithelial to
mesenchymal transition. J Biol Chem. 289:930–941. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Dai J, Wang JY, Yang LL, Xiao Y, Qu ZL,
Qin SH and Ruan QR: Correlation of Forkhead Box c2 with subtypes
and invasive ability of invasive breast cancer. J Huazhong Univ Sci
Technolog Med Sci. 34:896–901. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lim JC, Koh VC, Tan JS, Tan WJ, Thike AA
and Tan PH: Prognostic significance of epithelial-mesenchymal
transition proteins Twist and Foxc2 in phyllodes tumours of the
breast. Breast Cancer Res Treat. 150:19–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Taube JH, Herschkowitz JI, Komurov K, Zhou
AY, Gupta S, Yang J, Hartwell K, Onder TT, Gupta PB, Evans KW, et
al: Core epithelial-to-mesenchymal transition interactome
gene-expression signature is associated with claudin-low and
metaplastic breast cancer subtypes. Proc Natl Acad Sci USA.
107:15449–15454. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Mani SA, Yang J, Brooks M, Schwaninger G,
Zhou A, Miura N, Kutok JL, Hartwell K, Richardson AL and Weinberg
RA: Mesenchyme forkhead 1 (FOXC2) plays a key role in metastasis
and is associated with aggressive basal-like breast cancers. Proc
Natl Acad Sci USA. 104:10069–10074. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kume T: Foxc2 transcription factor: A
newly described regulator of angiogenesis. Trends Cardiovasc Med.
18:224–228. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Finlay J, Roberts CM, Lowe G, Loeza J,
Rossi JJ and Glackin CA: RNA-based TWIST1 inhibition via dendrimer
complex to reduce breast cancer cell metastasis. Biomed Res Int.
2015:3827452015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Tang H, Massi D, Hemmings BA, Mandalà M,
Hu Z, Wicki A and Xue G: AKT-ions with a TWIST between EMT and MET.
Oncotarget. 7:62767–62777. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Yang J, Mani SA, Donaher JL, Ramaswamy S,
Itzykson RA, Come C, Savagner P, Gitelman I, Richardson A and
Weinberg RA: Twist, a master regulator of morphogenesis, plays an
essential role in tumor metastasis. Cell. 117:927–939. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Watanabe O, Imamura H, Shimizu T,
Kinoshita J, Okabe T, Hirano A, Yoshimatsu K, Konno S, Aiba M and
Ogawa K: Expression of twist and wnt in human breast cancer.
Anticancer Res. 24:3851–3856. 2004.PubMed/NCBI
|
|
46
|
Giordano A, Gao H, Anfossi S, Cohen E,
Mego M, Lee BN, Tin S, De Laurentiis M, Parker CA and Alvarez RH:
Epithelial-mesenchymal transition and stem cell markers in patients
with HER2-positive metastatic breast cancer. Mol Cancer Ther.
11:2526–2534. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Micalizzi DS, Farabaugh SM and Ford HL:
Epithelial-mesenchymal transition in cancer: Parallels between
normal development and tumor progression. J Mammary Gland Biol
Neoplasia. 15:117–134. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Cheng GZ, Chan J, Wang Q, Zhang W, Sun CD
and Wang LH: Twist transcriptionally up-regulates AKT2 in breast
cancer cells leading to increased migration, invasion and
resistance to paclitaxel. Cancer Res. 67:1979–1987. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Arboleda MJ, Lyons JF, Kabbinavar FF, Bray
MR, Snow BE, Ayala R, Danino M, Karlan BY and Slamon DJ:
Overexpression of AKT2/protein kinase Bbeta leads to up-regulation
of beta1 integrins, increased invasion, and metastasis of human
breast and ovarian cancer cells. Cancer Res. 63:196–206.
2003.PubMed/NCBI
|
|
50
|
Irie HY, Pearline RV, Grueneberg D, Hsia
M, Ravichandran P, Kothari N, Natesan S and Brugge JS: Distinct
roles of Akt1 and Akt2 in regulating cell migration and
epithelial-mesenchymal transition. J Cell Biol. 171:1023–1034.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Kasimir-Bauer S, Hoffmann O, Wallwiener D,
Kimmig R and Fehm T: Expression of stem cell and
epithelial-mesenchymal transition markers in primary breast cancer
patients with circulating tumor cells. Breast Cancer Res.
14:R152012. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Ginestier C, Hur MH, Charafe-Jauffret E,
Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG,
Liu S, et al: ALDH1 is a marker of normal and malignant human
mammary stem cells and a predictor of poor clinical outcome. Cell
Stem Cell. 1:555–567. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Liu Y, Lv DL, Duan JJ, Xu SL, Zhang JF,
Yang XJ, Zhang X, Cui YH, Bian XW and Yu SC: ALDH1A1 expression
correlates with clinicopathologic features and poor prognosis of
breast cancer patients: A systematic review and meta-analysis. BMC
Cancer. 14:4442014. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Morimoto K, Kim SJ, Tanei T, Shimazu K,
Tanji Y, Taguchi T, Tamaki Y, Terada N and Noguchi S: Stem cell
marker aldehyde dehydrogenase 1-positive breast cancers are
characterized by negative estrogen receptor, positive human
epidermal growth factor receptor type 2 and high Ki67 expression.
Cancer Sci. 100:1062–1068. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Pan H, Wu N, Huang Y, Li Q, Liu C, Liang
M, Zhou W, Liu X and Wang S: Aldehyde dehydrogenase 1 expression
correlates with the invasion of breast cancer. Diagn Pathol.
10:662015. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Aktas B, Tewes M, Fehm T, Hauch S, Kimmig
R and Kasimir-Bauer S: Stem cell and epithelial-mesenchymal
transition markers are frequently overexpressed in circulating
tumor cells of metastatic breast cancer patients. Breast Cancer
Res. 11:R462009. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
